查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1402600

基因组癌症测试市场：按测试类型、按癌症类型、按技术、按最终用户、按生物标记类型、按服务供应商、按地区

Genomic Cancer Testing Market, By Test Type, By Cancer Type, By Technology, By End-User, By Biomarker Type, By Service Provider, By Application, By Testing Setting, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3个工作天内

价格
简介目录

全球基因组癌症检测市场规模预计将从 2023 年的 161.5 亿美元增加到 2030 年的 476.2 亿美元，预测期内复合年增长率为 16.7%。

报告范围 报告详情
基准年 2022年 2023年市场规模 161.5亿美元
实际资料 2018-2021 预测期 2023-2030
预测期复合年增长率 16.70% 2030年市场规模预测 476.2亿美元
图 1. 2023 年按地区分類的基因组癌症检测全球市场占有率(%)
基因组癌症检测市场-IMG1

基因组癌症检测正在迅速改变肿瘤学领域。此测试分析癌细胞的基因组成，以深入了解导致患者疾病的突变。这种个体化方法使临床医生能够根据个体的遗传特征量身定制治疗方案，并选择直接针对存在的异常的治疗药物。肿瘤基因组分析可以帮助预测对某些药物的反应，检查显示高復发风险的遗传标记，并确定可以阻断以阻止癌症生长的生物途径。随着基因组技术的不断进步，癌症检测变得更加全面且负担得起。预计这将在未来几年显着改善许多癌症患者的治疗结果。

市场动态：

全球基因组癌症检测市场主要是由全球癌症发生率上升以及由此产生的对精准医学方法的需求所推动的。次世代定序（NGS）技术在生物标记识别中的日益增长的应用也推动了市场的成长。然而，特别是在开发中国家，缺乏基因组分析所需的基础设施和熟练专家是一个主要问题。测试程序的高成本进一步限制了普及。然而，私人和公共机构为开发新型诊断工具提供的资金提供了利润丰厚的机会。诊断公司和癌症中心之间的合作旨在扩大基因组分析的范围。其他检测可操作的基因组改变和检验诊断的策略措施将进一步刺激基因伴同性癌症检测市场。此外，市场参与企业之间加强合作预计将在预测期内推动市场成长。例如，2023年4月，人工智慧和精准医疗领域的领导者Tempus宣布推出针对进行性或转移性甲状腺髓样癌（MTC）或进行性或转移性非髓样癌（non-MTC）的新技术。 ）今天宣布了一项由礼来公司赞助的新合作伙伴关係，旨在扩大合格的癌症患者获得基因组检测的机会。此次合作将免费提供 Tempus 的分子分析，同时与医生合作，透过广泛的基因组测试帮助为患者提供资料驱动的治疗。

本研究的主要特点

  • 本报告对全球基因组癌症检测市场进行了详细分析，并列出了以2022年为基准年的预测期（2023-2030）的市场规模和復合年增长率。
  • 它还揭示了各个细分市场的潜在商机，并为该市场说明了一系列有吸引力的投资提案。
  • 它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
  • 它根据公司亮点、产品系列、主要亮点、财务表现和策略等参数，介绍了全球基因组癌症检测市场的主要企业。
  • 该报告的见解将使行销人员和公司负责人能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
  • 全球基因组癌症检测市场报告针对该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
  • 透过用于分析全球基因组癌症检测市场的各种策略矩阵，将有助于相关人员做出决策。

目录

第一章 研究目的与前提

  • 研究目标
  • 先决条件
  • 简称

第二章 市场展望

  • 报告说明
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map（COM）

第三章市场动态、法规及趋势分析

  • 市场动态
    • 癌症发生率增加
    • 成本高
    • 癌症发生率增加
  • 影响分析
  • 主要亮点
  • 监管场景
  • 产品发布/核准
  • PEST分析
  • 波特的分析
  • 併购场景

第四章全球基因组癌症检测市场 -冠状病毒(COVID-19) 大流行的影响

  • 新型冠状病毒感染疾病（COVID-19）的流行病学
  • 供需面分析
  • 经济影响

第 5 章 2018-2030 年全球基因组癌症检测市场（依检测类型）

  • 基因组分析测试
  • 液体活体组织切片测试
  • 伴同性诊断测试
  • 药物基因组测试
  • 遗传性癌症检测
  • 其他专门的基因组测试

第 6 章 全球基因组癌症检测市场（以癌症类型），2018-2030 年

  • 乳癌
  • 肺癌
  • 大肠直肠癌
  • 摄护腺癌
  • 卵巢癌
  • 黑色素瘤
  • 白血病
  • 淋巴瘤
  • 某些其他癌症类型

第 7 章 2018-2030 年全球基因组癌症检测市场（按技术）

  • 下一代定序（NGS）
  • 聚合酶炼式反应 (PCR)
  • 萤光原位杂合反应（FISH）
  • 微阵列
  • 免疫组织化学 (IHC)
  • 其他基因组测试技术

第 8 章 全球基因组癌症检测市场，依最终用户划分，2018-2030 年

  • 医院
  • 诊断实验室
  • 学术研究所
  • 癌症中心
  • 其他医疗保健提供者

第 9 章 全球基因组癌症检测市场（依生物标记类型），2018-2030 年

  • 基因生物标记
  • 蛋白质生物标记
  • 分子生物标记
  • 磊晶生物标记

第 10 章 全球基因组癌症检测市场（按服务供应商划分），2018-2030 年

  • 诊断实验室
  • 生技公司
  • 製药公司
  • 受託研究机构（CRO）

第十一章 全球基因组癌症检测市场（按地区），2018-2030

  • 北美洲
  • 美国
  • 加拿大
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
  • 欧洲
  • 英国
  • 德国
  • 义大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韩国
  • 其他亚太地区
  • 中东
  • GCC
  • 以色列
  • 其他中东地区
  • 非洲
  • 北非
  • 中部非洲
  • 南非

第十二章竞争形势

  • Illumina, Inc.
  • Thermo Fisher Scientific, Inc.
  • Qiagen NV
  • F.Hoffmann-La Roche Ltd.
  • Foundation Medicine, Inc.（Roche）
  • Invitae Corporation
  • NeoGenomics Laboratories, Inc.
  • Myriad Genetics, Inc.
  • Genomic Health, Inc.（Exact Sciences Corporation）
  • Caris Life Sciences
  • ArcherDX, Inc.（Invitae Corporation）
  • Guardant Health, Inc.
  • Personal Genome Diagnostics Inc.
  • Biocept, Inc.
  • Tempus Labs, Inc.

第13章

  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI5914

The global genomic cancer testing market size is expected to reach US$ 47.62 billion by 2030, from US$ 16.15 billion in 2023, at a CAGR of 16.7% during the forecast period.

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 16.15 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 16.70% 2030 Value Projection: US$ 47.62 Bn
Figure 1. Global Genomic Cancer Testing Market Share (%), by Region, 2023
Genomic Cancer Testing Market - IMG1

Genomic cancer testing is rapidly transforming the field of oncology. It involves analyzing the genetic makeup of cancer cells to gain insights into the mutations driving a patient's disease. This personalized approach enables clinicians to tailor treatment based on an individual's genetic profile and select therapeutics that directly target the abnormalities present. The genomic analysis of a tumor helps predict response to certain drugs, checks for genetic markers that may indicate higher risk of recurrence, and pinpoints biological pathways that can be blocked to stop cancer growth. With continued advances in genomic technologies, cancer testing is becoming more comprehensive and affordable. This is expected to significantly improve outcomes for many cancer patients in the coming years.

Market Dynamics:

The global genomic cancer testing market is primarily driven by rising cancer burden worldwide and subsequent demand for precision medicine approaches. Growing application of next-generation sequencing (NGS) technologies for biomarker identification is also fueling market growth. However, lack of infrastructure and skilled professionals required for genomic analysis poses a major challenge, especially in developing nations. High cost of testing procedures further limits widespread adoption. Yet funding from private and public bodies to develop novel diagnostic tools presents lucrative opportunities. Partnerships between diagnostic companies and cancer centers aim to expand access to genomic profiling. Other strategic initiatives to detect actionable genomic alterations and validate companion diagnostics will further stimulate the genomic cancer testing market. MOrevoer, increasing collaboration between market players is expected to drive the market growth over forecast period. For instance, in April 2023, Tempus, a leader in artificial intelligence and precision medicine, today announced a new collaboration sponsored by Eli Lilly and Company designed to expand access to genomic testing for eligible patients who have advanced or metastatic medullary thyroid cancer (MTC) OR advanced or metastatic non-medullary thyroid cancer (non-MTC). This collaboration offers Tempus' molecular profiling offerings at no cost while simultaneously working with physicians to support them in providing data-driven treatment to their patients with the use of broad-panel genomic testing.

Key features of the study:

  • This report provides in-depth analysis of the global genomic cancer testing market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global genomic cancer testing market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Illumina, Inc., Thermo Fisher Scientific, Inc., Qiagen N.V., F. Hoffmann-La Roche Ltd., Foundation Medicine, Inc. (Roche), Invitae Corporation, NeoGenomics Laboratories, Inc., Myriad Genetics, Inc., Genomic Health, Inc. (Exact Sciences Corporation), Caris Life Sciences, ArcherDX, Inc. (Invitae Corporation), Guardant Health, Inc., Personal Genome Diagnostics Inc., Biocept, Inc., and Tempus Labs, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global genomic cancer testing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global genomic cancer testing market

Detailed Segmentation:

  • Global Genomic Cancer Testing Market, By Test Type:
    • Genomic Profiling Tests
    • Liquid Biopsy Tests
    • Companion Diagnostic Tests
    • Pharmacogenomic Tests
    • Hereditary Cancer Tests
    • Other specialized genomic tests
  • Global Genomic Cancer Testing Market, By Cancer Type:
    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Ovarian Cancer
    • Melanoma
    • Leukemia
    • Lymphoma
    • Other specific cancer types
  • Global Genomic Cancer Testing Market, By Technology:
    • Next-Generation Sequencing (NGS)
    • Polymerase Chain Reaction (PCR)
    • Fluorescence In Situ Hybridization (FISH)
    • Microarray
    • Immunohistochemistry (IHC)
    • Other genomic testing technologies
  • Global Genomic Cancer Testing Market, By End User:
    • Hospitals
    • Diagnostic Laboratories
    • Academic and Research Institutions
    • Cancer Centers
    • Other healthcare providers
  • Global Genomic Cancer Testing Market, By Biomarker Type:
    • Genetic Biomarkers
    • Protein Biomarkers
    • Molecular Biomarkers
    • Epigenetic Biomarkers
  • Global Genomic Cancer Testing Market, By Service Provider:
    • Diagnostic Laboratories
    • Biotechnology Companies
    • Pharmaceutical Companies
    • Contract Research Organizations (CROs)
  • Global Genomic Cancer Testing Market, By Application:
    • Targeted Therapy Selection
    • Disease Monitoring
    • Prognostic Testing
    • Companion Diagnostics
    • Risk Assessment
    • Pharmacogenomic Testing
  • Global Genomic Cancer Testing Market, By Testing Setting:
    • In-House Testing
    • Outsourced Testing
  • Global Genomic Cancer Testing Market, By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and Africa
  • Company Profiles:
    • Illumina, Inc.
    • Thermo Fisher Scientific, Inc.
    • Qiagen N.V.
    • F. Hoffmann-La Roche Ltd.
    • Foundation Medicine, Inc. (Roche)
    • Invitae Corporation
    • NeoGenomics Laboratories, Inc.
    • Myriad Genetics, Inc.
    • Genomic Health, Inc. (Exact Sciences Corporation)
    • Caris Life Sciences
    • ArcherDX, Inc. (Invitae Corporation)
    • Guardant Health, Inc.
    • Personal Genome Diagnostics Inc.
    • Biocept, Inc.
    • Tempus Labs, Inc.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Genomic Cancer Testing, By Test Type
    • Market Genomic Cancer Testing, By Cancer Type
    • Market Genomic Cancer Testing, By Technology
    • Market Genomic Cancer Testing, By End User
    • Market Genomic Cancer Testing, By Biomarker Type
    • Market Genomic Cancer Testing, By Service Provider
    • Market Genomic Cancer Testing, By Application
    • Market Genomic Cancer Testing, By Testing Setting
    • Market Genomic Cancer Testing, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Increasing Cancer Incidence
    • High Costs
    • Increasing Cancer Incidence
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Genomic Cancer Testing Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Genomic Cancer Testing Market , By Test Type, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Genomic Profiling Tests
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Liquid Biopsy Tests
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Companion Diagnostic Tests
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Pharmacogenomic Tests
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Hereditary Cancer Tests
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Other specialized genomic tests
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

6. Global Genomic Cancer Testing Market , By Cancer Type, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Breast Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Lung Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Colorectal Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Prostate Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Ovarian Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Melanoma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Leukemia
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Lymphoma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Other specific cancer types
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

7. Global Genomic Cancer Testing Market , By Technology, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Next-Generation Sequencing (NGS)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Polymerase Chain Reaction (PCR)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Fluorescence In Situ Hybridization (FISH)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Microarray
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Immunohistochemistry (IHC)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Other genomic testing technologies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

8. Global Genomic Cancer Testing Market , By End User, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Diagnostic Laboratories
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Academic and Research Institutions
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Cancer Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Other healthcare providers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

9. Global Genomic Cancer Testing Market , By Biomarker Type, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Genetic Biomarkers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Protein Biomarkers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Molecular Biomarkers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Epigenetic Biomarkers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

10. Global Genomic Cancer Testing Market , By Service Provider, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019- 2030
    • Segment Trends
  • Diagnostic Laboratories
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Biotechnology Companies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Pharmaceutical Companies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Contract Research Organizations (CROs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

11. Global Genomic Cancer Testing Market , By Region, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Region, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Region, 2019-2030
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Service Provider, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Testing Setting, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • North Africa
  • Central Africa
  • South Africa

12. Competitive Landscape

  • Illumina, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Thermo Fisher Scientific, Inc.
  • Qiagen N.V.
  • F.Hoffmann-La Roche Ltd.
  • Foundation Medicine, Inc. (Roche)
  • Invitae Corporation
  • NeoGenomics Laboratories, Inc.
  • Myriad Genetics, Inc.
  • Genomic Health, Inc. (Exact Sciences Corporation)
  • Caris Life Sciences
  • ArcherDX, Inc. (Invitae Corporation)
  • Guardant Health, Inc.
  • Personal Genome Diagnostics Inc.
  • Biocept, Inc.
  • Tempus Labs, Inc.
  • Analyst Views

13. Section

  • Research Methodology
  • About us